

March 10 08

U. S. Food & Drug Adm.

Dockets Branch

RE: Docket No. 00N-0989

Regarding the proposed FDA rule that could provide public access to most of the study design and safety information on all new or ongoing clinical trials involving either gene therapy or xenotransplantation:

This proposal ~~only~~ brings gene therapy and xenotransplantation in compliance with the same types of information already released to the public by other government agencies. Because of grave public health risks, disclosure should include additional information such as physicians, medical centers, and so on - make public all information except trade secrets and patient identification.

The FDA must assume the sole responsibility for summarizing and distributing information submitted by the research sponsor, rather than leave it to the sponsor's discretion.

Because of the public health risks, ethical issues, cost uncertainty, and the inability to adequately assess other alternatives, all xenotransplantation clinical trials should stop.

Sincerely,

Dorothy Finger

Dorothy Finger (Mrs.)


12675 Skyline Blvd.

Oakland Ca 94619

C20

00N-0989

Mrs. Dorothy Finger
12675 Skyline Boulevard
Oakland, CA 94619



U S Food & Drug Adm.
Dockets Management Branch
5630 Fishers Lane Rm. 1061 HFA-305
Rockville MD 20852

